AZRX vs. VIRI, WHWK, OSTX, ELYM, ATNM, NBRV, AADI, EGRX, PYRGF, and NNVC
Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and NanoViricides (NNVC).
AzurRx BioPharma vs. Its Competitors
Virios Therapeutics (NASDAQ:VIRI) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.
Virios Therapeutics' return on equity of -130.33% beat AzurRx BioPharma's return on equity.
In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled AzurRx BioPharma'saverage media sentiment score.
9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 7.3% of AzurRx BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Virios Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 3.52%. Given Virios Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Virios Therapeutics is more favorable than AzurRx BioPharma.
Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Virios Therapeutics is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
Virios Therapeutics beats AzurRx BioPharma on 9 of the 10 factors compared between the two stocks.
Get AzurRx BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AzurRx BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:AZRX) was last updated on 9/10/2025 by MarketBeat.com Staff
